200 related articles for article (PubMed ID: 21407201)
41. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
42. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
44. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
[TBL] [Abstract][Full Text] [Related]
45. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
46. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
[TBL] [Abstract][Full Text] [Related]
47. Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence.
Dunlop EA; Dodd KM; Land SC; Davies PA; Martins N; Stuart H; McKee S; Kingswood C; Saggar A; Corderio I; Medeira AM; Kingston H; Sampson JR; Davies DM; Tee AR
Eur J Hum Genet; 2011 Jul; 19(7):789-95. PubMed ID: 21407264
[TBL] [Abstract][Full Text] [Related]
48. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.
Li S; Takeuchi F; Wang JA; Fuller C; Pacheco-Rodriguez G; Moss J; Darling TN
J Exp Med; 2005 Sep; 202(5):617-24. PubMed ID: 16129702
[TBL] [Abstract][Full Text] [Related]
49. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
50. Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice.
Cao J; Gong L; Guo DC; Mietzsch U; Kuang SQ; Kwartler CS; Safi H; Estrera A; Gambello MJ; Milewicz DM
Hum Mol Genet; 2010 May; 19(10):1908-20. PubMed ID: 20159776
[TBL] [Abstract][Full Text] [Related]
51. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
52. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.
Krymskaya VP; Goncharova EA
Cell Cycle; 2009 Feb; 8(3):403-13. PubMed ID: 19177005
[TBL] [Abstract][Full Text] [Related]
53. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
[TBL] [Abstract][Full Text] [Related]
54. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
55. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition.
Bhaskar PT; Nogueira V; Patra KC; Jeon SM; Park Y; Robey RB; Hay N
Mol Cell Biol; 2009 Sep; 29(18):5136-47. PubMed ID: 19620286
[TBL] [Abstract][Full Text] [Related]
56. Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules.
Armour EA; Carson RP; Ess KC
Am J Physiol Renal Physiol; 2012 Aug; 303(4):F584-92. PubMed ID: 22674026
[TBL] [Abstract][Full Text] [Related]
57. [Tuberous Sclerosis Complex].
Kaneda M
Brain Nerve; 2019 Apr; 71(4):374-379. PubMed ID: 30988224
[TBL] [Abstract][Full Text] [Related]
58. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.
Zhang J; Kim J; Alexander A; Cai S; Tripathi DN; Dere R; Tee AR; Tait-Mulder J; Di Nardo A; Han JM; Kwiatkowski E; Dunlop EA; Dodd KM; Folkerth RD; Faust PL; Kastan MB; Sahin M; Walker CL
Nat Cell Biol; 2013 Oct; 15(10):1186-96. PubMed ID: 23955302
[TBL] [Abstract][Full Text] [Related]
59. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
60. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
